Hong Kong vs Peru: The number of people with susceptibility test result for rifampicin
Hong Kong
94.83
in 2021
Peru
94.02
in 2021
Hong Kong rank
52nd
Peru rank
55th
The number of people with susceptibility test result for rifampicin over time
- Hong Kong
- Peru
How they compare
Hong Kong currently reports 94.83 against 94.02 in Peru, a difference of 0.81.
Across all 5 years both countries report, Hong Kong has been ahead every year.
Hong Kong ranks 52nd and Peru ranks 55th of 146 countries.
Hong Kong has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Hong Kong | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 96.18 | 76.94 | 19.24 | Hong Kong |
| 2020s | 94.72 | 82.99 | 11.72 | Hong Kong |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Hong Kong or Peru?
- Hong Kong, at 94.83 against 94.02 in Peru as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Hong Kong and Peru?
- 0.81, with Hong Kong ahead.
- How many years of comparable data are there for Hong Kong and Peru?
- 5 years are reported by both, from 2017 to 2021.
- How do Hong Kong and Peru rank globally for the number of people with susceptibility test result for rifampicin?
- Hong Kong ranks 52nd and Peru ranks 55th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.